

Canaan

Brent Ahrens

General Partner / West Coast

Since 2010

Brent joined Canaan in 1999 as a member of the Kauffman Fellows Program and throughout his tenure has lead investments in an array of healthcare companies, with a focus on biopharma and medtech. Brent's current investments and board seats include device developer and manufacturer Abyrx, reflux device company EndoGastric Solutions, immune-oncology drug developer Grey Wolf Therapeutics, antibiotic developer Iterum Therapeutics, autoimmune disease therapy provider Pathios Therapeutics, device maker for chronic back pain Relieva MedSystems, life sciences tool company Unchained Labs, and pain management developer Scilex Pharmaceuticals.

His previous companies include Dexcom (DXCM), Revivant (acquired by ZOLL), Peninsula Pharmaceuticals (acquired by JNJ), Cerexa (acquired by FRX), Calixa (acquired by CBST), AtheroMed (acquired by VOLC); Durata Therapeutics (DRTX, acquired by AGN), Data Sciences International (acquired by HBIO); Elevation Pharmaceuticals (acquired by DNPUF); and Spinifex (acquired by NVS).

Prior to joining Canaan, Brent worked in both commercial and technical roles at General Surgical Innovations, Ethicon Endo-Surgery (J&J), and IAP Research. He also has several surgical instrument patents to his credit.

Brent earned an M.B.A. from the Tuck School of Business at Dartmouth College after graduating with a B.S. and M.S. in Mechanical Engineering from the University of Dayton.

About Canaan

Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With \$5B under management, a diversified fund and over 200 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 32 years. Canaan's focus areas include consumer tech, fintech, enterprise/SaaS, frontier tech, biopharma, digital health and medtech. To learn more about our people and our portfolio, please visit canaan.com.